Literature DB >> 29240640

Indocyanine Green Angiography Use in Breast Reconstruction: A National Analysis of Outcomes and Cost in 110,320 Patients.

Anmol Chattha1,2, Alexandra Bucknor1,2, Austin D Chen1,2, Bernard T Lee1,2, Samuel J Lin1,2.   

Abstract

BACKGROUND: Indocyanine green angiography has gained popularity in breast reconstruction for its ability to assess mastectomy skin and tissue flap viability. The authors aim to analyze trends and outcomes associated with indocyanine green angiography use in breast reconstruction.
METHODS: Using 2012 to 2014 data from the Healthcare Cost and Utilization Project National Inpatient Sample, Agency for Healthcare Research and Quality, the authors identified breast reconstructions performed with or without indocyanine green angiography use. Trends over time were assessed using the Cochran-Armitage test. Outcomes were assessed using logistic regression and generalized linear modeling.
RESULTS: Over the study period, 110,320 patients underwent breast reconstruction: 107,005 (97.0 percent) without and 3315 (3.0 percent) with indocyanine green angiography use. Usage increased over time: 750 patients (1.9 percent) in 2012, increasing to 1275 patients (3.7 percent) in 2013 (p < 0.001). Smokers (p = 0.018), hypertensive patients (p = 0.046), obese patients (p < 0.001), and those with a higher comorbidity index (p < 0.001) were more likely to undergo indocyanine green angiography. Autologous reconstruction was more frequently combined with its use compared with tissue expander reconstruction (4.5 percent versus 2.1 percent; p < 0.001). There was a significant increase in the odds of débridement associated with its use (OR, 1.404; p < 0.001; 95 percent CI, 1.201 to 1.640).
CONCLUSIONS: Indocyanine green angiography use in breast reconstruction has increased in recent years and is associated with higher débridement rates. These rates may indicate changing trends for clinicians when deciding whether to débride tissue during breast reconstruction. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, III.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29240640     DOI: 10.1097/PRS.0000000000004195

Source DB:  PubMed          Journal:  Plast Reconstr Surg        ISSN: 0032-1052            Impact factor:   4.730


  5 in total

Review 1.  Implant Reconstruction in Nipple Sparing Mastectomy.

Authors:  Carrie K Chu; Matthew J Davis; Amjed Abu-Ghname; Sebastian J Winocour; Albert Losken; Grant W Carlson
Journal:  Semin Plast Surg       Date:  2019-10-17       Impact factor: 2.314

2.  [Multivariable analysis for flap-related complications in autologous breast reconstruction and economic analysis of intraoperative indocyanine green angiography].

Authors:  Zeyang Liu; Zan Li; Xiaowei Peng; Bo Zhou; Yuanyuan Tang; Peng Wu; Dajiang Song; Chunliu Lü; Wen Peng; Hui Li; Yan Ou; Anji Xu
Journal:  Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi       Date:  2020-01-15

3.  Immediate Prepectoral Breast Reconstruction in Suboptimal Patients Using an Air-filled Spacer.

Authors:  Hilton Becker; Prakash J Mathew
Journal:  Plast Reconstr Surg Glob Open       Date:  2019-10-21

4.  Use of Indocyanine Green Angiography for Real-Time Assessment of a Sternocleidomastoid Muscle Flap During Complex Facial Reconstruction.

Authors:  Lisandro Montorfano; Stephen J Bordes; Mauricio Sarmiento Cobos; Emmanuel Alejandro Garcia Lopez; Michael Medina
Journal:  Cureus       Date:  2021-03-18

5.  Assessing the development status of intraoperative fluorescence imaging for perfusion assessments, using the IDEAL framework.

Authors:  Takeaki Ishizawa; Peter McCulloch; Derek Muehrcke; Thomas Carus; Ory Wiesel; Giovanni Dapri; Sylke Schneider-Koriath; Steven D Wexner; Mahmoud Abu-Gazala; Luigi Boni; Elisa Cassinotti; Charles Sabbagh; Ronan Cahill; Frederic Ris; Michele Carvello; Antonino Spinelli; Eric Vibert; Muga Terasawa; Mikiya Takao; Kiyoshi Hasegawa; Rutger M Schols; Tim Pruimboom; Yasuo Murai; Fumihiro Matano; Michael Bouvet; Michele Diana; Norihiro Kokudo; Fernando Dip; Kevin White; Raul J Rosenthal
Journal:  BMJ Surg Interv Health Technol       Date:  2021-10-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.